Praxis Precision Medicines Publishes Investor Day Presentation
- Praxis Precision Medicines published its Investor Day presentation: https://www.globenewswire.com/Tracker?data=RlwjPiF3qfFUIdfWa2iJjDxfz_3VCObMKdCl2F1AINbmzKhKsQh-UrYAtJZulQzlOHy04VKg5jf1D5HYAxAndTlmi5APa0NgLsF7nhmYsOE8Ei5Aux2jmtdN8ndrx-2UB1RATI7jnlbbK5GIEP4bPYf2D4zCZDBbJEJdaSlqxLc=.
- Launch preparations target FDA action dates of December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide.
- Relutrigine extension data showed an 86% seizure reduction from baseline through 18 months; ulixacaltamide showed improving daily-living response at approximately 95 weeks.
- Ulixacaltamide studies in Parkinson's disease, restless legs syndrome and autism spectrum disorder are planned to begin in 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121630PRIMZONEFULLFEED9876874) on November 12, 2026, and is solely responsible for the information contained therein.